Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial.

Kanwal RaghavSalvatore SienaAtsuo TakashimaTakeshi KatoMarc Van den EyndeFilippo PietrantonioYoshito KomatsuHisato KawakamiMarc PeetersThierry AndreSara LonardiKensei YamaguchiJeanne TieCristina Gravalos CastroHung-Chih HsuJohn H StricklerTae-You KimYongjun ChaDaniel BarriosQi YanTakahiro KamioKojiro KobayashiAislyn BoranMakito KogaJohn D AllardTakayuki Yoshino

Published in: The Lancet. Oncology (2024)

Daiichi Sankyo and AstraZeneca.

Keyphrases

clinical trial
double blind
study protocol
open label
placebo controlled
epidermal growth factor receptor
randomized controlled trial
metastatic breast cancer
tyrosine kinase